Aardvark Therapeutics
San Diego based pharmaceutical company specializing in gut brain interaction with a focus of inflammation and metabolism
https://aardvarktherapeutics.com/
11-50 employees
Growth Trajectory
Aardvark's growth lies in expanding the applications of ARD-101 and ARD-201, particularly in the broader obesity market. Clinical trials are underway, signaling potential for rapid expansion upon successful regulatory approvals. Partnering opportunities and further development of TAS2R-targeted therapies also represent significant growth avenues.
Technical Challenges
Achieving gut-localized action and minimizing systemic exposure of drugs.
Scaling up manufacturing of drug substance (API) and drug product (DP).
Designing and executing successful clinical trials.
Integrating ARD-101 with a DPP-4 inhibitor in a fixed-dose combination.
Tech Stack
Small-molecule therapeuticsTAS2R activationOral drug deliveryFixed-dose combination therapiesGut-localized hormone modulation
Team Size
Key Risks
Regulatory approval hurdles for novel therapies.
Competition from established GLP-1 therapies for obesity.
Manufacturing and scaling challenges for drug product (API).
Potential setbacks in clinical trials.
Opportunities
Addressing unmet needs in hyperphagia treatment for rare diseases and obesity.
Expanding into the broader obesity market with ARD-201.
Leveraging the favorable safety profile of ARD-101 due to limited systemic exposure.
Exploring partnering opportunities for clinical trials and business development.
Live Data Stream
Access Our Live VC Funding Database
30,000+ funded startups
tracked in the last 3 months
B2B verified emails
of key decision makers
Growth metrics
Real-time company performance data
Live updates
of new VC funding rounds
Advanced filters
for sophisticated queries
API access
with multiple export formats